Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Share-based Compensation: 2020-2025

Historic Share-based Compensation for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $10.6 million.

  • GeneDx Holdings' Share-based Compensation rose 191.14% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 368.82%. This contributed to the annual value of $9.1 million for FY2024, which is 2903.07% up from last year.
  • As of Q3 2025, GeneDx Holdings' Share-based Compensation stood at $10.6 million, which was up 35.49% from $7.8 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Share-based Compensation peaked at $165.0 million during Q1 2021, and registered a low of -$912,000 during Q4 2023.
  • In the last 3 years, GeneDx Holdings' Share-based Compensation had a median value of $2.8 million in 2024 and averaged $2.8 million.
  • In the last 5 years, GeneDx Holdings' Share-based Compensation skyrocketed by 4,477.84% in 2022 and then crashed by 1,039.58% in 2024.
  • Over the past 5 years, GeneDx Holdings' Share-based Compensation (Quarterly) stood at $37.0 million in 2021, then tumbled by 98.86% to $422,000 in 2022, then tumbled by 316.11% to -$912,000 in 2023, then skyrocketed by 411.95% to $2.8 million in 2024, then spiked by 191.14% to $10.6 million in 2025.
  • Its Share-based Compensation stands at $10.6 million for Q3 2025, versus $7.8 million for Q2 2025 and $4.0 million for Q1 2025.